Pfizer

This study tests a fifth dose of Pfizer's Lyme disease vaccine (VLA15) in healthy people aged 7 and older who already received four doses. The goal is to see if the booster is safe and boosts the immune system's ability to fight Lyme disease. Participants will get either the vacc…

This study tests an experimental vaccine designed to protect against E. coli bacteria. Researchers want to see if the vaccine is safe and tolerable in healthy adults aged 18 to 64. About 310 volunteers will receive the vaccine or a placebo and be monitored for side effects like i…

This study checks if giving a second RSV vaccine dose to pregnant women during a later pregnancy is safe and boosts immunity. About 550 women who received the vaccine in a prior pregnancy will take part. Researchers will monitor side effects and measure antibody levels in mothers…

This study is checking the safety of the Prevenar 20 vaccine after it is already available in Korea. About 660 people aged 6 weeks and older who are prescribed the vaccine will take part. Researchers will track any side effects for 28 days after the shot.

This study tests a vaccine given to pregnant women to help protect their babies from group B streptococcus (GBS), a bacteria that can cause serious illness in newborns. About 6,000 healthy pregnant women will receive either the vaccine or a placebo (saltwater shot). Researchers w…

This study looks at how well a 20-valent pneumococcal vaccine works against pneumonia in adults aged 65 and older who are hospitalized with the infection. Participants provide a urine sample and medical history, and researchers compare vaccination rates between those with vaccine…

This study tests whether a vaccine can prevent C. difficile infection, a serious gut infection often linked to antibiotic use. About 32,000 adults aged 65 and older will receive either the vaccine or a placebo shot. Researchers will track how many people get C. diff diarrhea over…

This study tests an experimental mRNA flu vaccine in healthy adults aged 18 and older. Researchers want to see if it is safe and triggers a strong immune response. Participants receive one shot and are followed for about 6 months with blood tests and a nasal swab. The results wil…

This study looks at the safety and effectiveness of Velsipity tablets taken daily for up to 52 weeks by people with moderate to severe ulcerative colitis. About 553 participants will be followed in real-world medical settings. The goal is to see if the drug can help control sympt…

This study tests an experimental pill (PF-07328948) for adults with heart failure. About 620 participants will receive either the drug or a placebo to see if it improves walking distance, symptoms, and reduces heart-related events. The goal is to better control the disease and im…

This study tests a new drug, PF-07248144, combined with fulvestrant for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatment. About 400 adults will be randomly assigned to receive either the new combination or…

This study looks at the long-term safety of a medicine called dazukibart for people with dermatomyositis or polymyositis, which are rare diseases that cause muscle weakness and can affect daily activities. About 211 adults who completed a previous dazukibart study will receive th…

This study tests an experimental pill called ibuzatrelvir in adults and teens with mild-to-moderate COVID-19 who are at high risk for severe illness. Participants take the pill or a placebo for 5 days at home. The goal is to see if the drug reduces emergency visits, hospitalizati…

This early-stage study tests a new oral medication, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see if it works alone or with other cancer treatments. About 260 adults will take the pill daily in 28-day…

This study tracks how effective and safe the drug lorlatinib is for people with advanced ALK-positive non-small cell lung cancer who have not had treatment before. Researchers will follow about 90 patients in France to see how long they live without the cancer growing and their o…

This study tests whether adding the experimental drug elranatamab to two standard medications (daratumumab and lenalidomide) works better than the usual four-drug combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. About 1…

This study tests a new drug, PF-08046054, against the standard chemo docetaxel in people with advanced non-small cell lung cancer that has PD-L1 protein and has stopped responding to prior treatments. About 680 adults will be randomly assigned to one of the two drugs, given as IV…

This study is testing a new antibiotic combination (aztreonam-avibactam) in hospitalized children aged 9 months to 18 years with serious gram-negative bacterial infections. The goal is to see how the drug is processed in the body, how safe it is, and how well it works compared to…

This study tests a new drug, elranatamab, given as a weekly shot, against standard drug combinations for multiple myeloma that has returned or stopped responding to treatment. About 492 adults who have already tried other therapies will take part. The goal is to see if elranatama…

This study watches adults in Korea who are already receiving Mylotarg for newly diagnosed acute myeloid leukemia (AML). Researchers will track side effects and how the disease responds. The goal is to learn more about the drug's safety and effects in real-world use. No new treatm…

This study gives people with solid tumors who are already benefiting from encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. Participants must have been in a prior encorafenib/binimetinib study and still be getting benefit with…

This study tests an experimental drug called PF-07248144 in people with advanced or metastatic breast, prostate, or lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe, tolerable, and can shrink or control tumors. About 320 participan…

This study looks at how well the oral medication abrocitinib works for people with moderate-to-severe eczema (atopic dermatitis) who have already tried up to two biologic drugs without success or had side effects. About 150 participants aged 12 and older will be followed in real-…

This study tests a new medicine, PF-08634404, given alone or with another drug (ipilimumab) for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and shrinks tumors. About 138 participants will receive the drug throug…

This study follows 300 adults with moderate to severe ulcerative colitis who are prescribed etrasimod as part of their regular care. Researchers will track symptom changes over 52 weeks using health questionnaires completed on a phone or computer. The goal is to see how well etra…

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 550 participants will receive either the new drug plus chemo or an approved treatment to see which wo…

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants get the drug alone, others get it with another cancer drug. The goal is to see if the treatment is safe and shrinks tumors.

This early-stage study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This early-stage study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests if adding an experimental drug (PF-06821497) to the standard treatment enzalutamide works better than enzalutamide alone for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 900 participants will receive either the com…

This study is tracking the safety and effects of the medicine Litfulo in 3,000 adults and teens with severe alopecia areata, a condition causing major hair loss. Participants take the drug as prescribed by their doctor, and researchers monitor side effects and hair regrowth over …

This study tests whether a targeted drug called inotuzumab ozogamicin works better than standard chemotherapy (ALLR3) for children aged 1 to 17 with high-risk or very high-risk B-cell acute lymphoblastic leukemia that has come back for the first time. About 100 participants will …

This study looks at the long-term safety of a drug called marstacimab for people with severe hemophilia A or B. It is for those who already completed an earlier study. The goal is to see if the drug is safe and helps prevent bleeding episodes over time. About 245 participants wil…

This study tests a new medicine called PF-08634404, given with chemotherapy, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops after other treatments stop working. About 40 participants who have not yet been treated for T-SCLC…

This study tests a new experimental drug (PF-07934040) in people with advanced solid tumors that have a KRAS gene mutation, including certain lung, colon, and pancreatic cancers. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV…

This study tests the long-term safety and effectiveness of a daily liquid medicine called abrocitinib for children aged 2 and older with moderate-to-severe eczema. About 500 kids will take the medicine for up to 24 months, with or without topical creams. The goal is to see if the…

This program provides early access to the drug etrasimod for people with severe ulcerative colitis who have tried at least three other treatments without success or cannot use them. The goal is to offer a potential treatment option when no standard therapies are available. Patien…

This study tests an experimental drug called dazukibart for people with active dermatomyositis or polymyositis, rare diseases that cause muscle weakness and sometimes skin rash. About 318 adults will receive either the drug or a placebo by IV every 4 weeks for 48 weeks, while con…

This study tracks 183 adults with moderate-to-severe atopic dermatitis (eczema) who take abrocitinib tablets daily for up to 24 months. Researchers want to see how well the drug clears skin and eases symptoms in real-life settings, not just in controlled trials. Participants can …

This study tests a new medicine called MET097, given as a weekly shot, to help adults who are overweight or have obesity and type 2 diabetes lose weight. About 1,000 people will take part; two-thirds get the real medicine and one-third get a placebo. The study lasts about 21 mont…

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung, esophageal, or skin cancer that has spread or can't be removed. The main goal is to check safety and find the right dose. Participants receive the drug in cycles and are closely watched for si…

This study looks at how safe and effective the drug BOSULIF is for people with chronic myeloid leukemia (CML) when used in regular medical practice. About 600 participants in Korea who are already taking or will start BOSULIF will be followed. The goal is to track side effects an…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. About 80 participants will continue treatment and be monitored for side effects. The goal is to keep providing the drug while c…

This study tests a new medicine (PF-08634404) combined with standard chemotherapy against an approved drug (bevacizumab) plus chemotherapy for people with colorectal cancer that has spread. About 800 adults who have not had prior treatment for metastatic disease will be randomly …

This study tests a medicine called disitamab vedotin in 100 adults with advanced HER2-positive breast cancer that has spread and is hard to treat. Participants receive the drug as an IV infusion every two weeks. The goal is to see if the drug can shrink tumors and to check its sa…

This study tests an oral drug called etrasimod in 36 adolescents (ages 12 to under 18) with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can safely reduce inflammation and help patients feel better over 52 weeks, with an option to…

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This study tests whether adding the experimental drug mevrometostat to the standard treatment enzalutamide can delay cancer growth better than enzalutamide alone in men with metastatic castration-sensitive prostate cancer. About 1,000 participants will be randomly assigned to rec…

This study tests whether a new drug called ibuzatrelvir, alone or with remdesivir, can help severely immunocompromised adults with symptomatic COVID-19 avoid hospitalization or death. About 300 participants will receive either ibuzatrelvir plus remdesivir, ibuzatrelvir alone, or …

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if it is safe and can shrink tumors when given alone or with other cancer drugs. About 224 participants will receive the drug through an IV. This is an early-ph…

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months in real-world settings, not a controlled lab. The goal is to see how well the drug…

This study tests a new drug, elranatamab, alone or with another drug (daratumumab) in people whose multiple myeloma has returned after at least one prior treatment. About 944 participants will be randomly assigned to one of three groups to see which approach works best and is saf…

This study looks at the long-term safety and effects of an experimental medicine called PF-07868489 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lung arteries makes the heart work harder. Adults who completed a prior study of…

This study tests a new medicine called marstacimab for people with severe hemophilia A who want to switch from their current treatment (emicizumab). Hemophilia A is a rare bleeding disorder where blood doesn't clot properly. The study will check if marstacimab is safe and how it …

This study is a post-marketing surveillance required by Korean regulators to monitor the safety and effectiveness of Xeljanz XR (tofacitinib) in everyday medical practice. It will enroll about 200 adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, or ankylo…

This study tests an experimental medicine called PF-07275315 for adults aged 18-70 with moderate-to-severe asthma that is not well controlled. Participants receive either the study drug or a placebo as injections over 12 weeks, with 9 clinic visits over about 7.5 months. The goal…

This study follows 120 people with ulcerative colitis in Sweden who are already prescribed tofacitinib as part of their normal care. Researchers will use a national registry to see how many achieve remission and stick with the treatment. The goal is to understand how well the dru…

This study follows people with hemophilia A or B who already received a one-time gene therapy (giroctocogene fitelparvovec or fidanacogene elaparvovec) in a previous Pfizer trial. Researchers will monitor their health over time to check for side effects and how well the treatment…

This study tests an oral drug called etrasimod in children aged 2 to under 12 with moderate to severe ulcerative colitis. The goal is to see if the drug can safely reduce inflammation and bring the disease under control. Participants will take the drug for up to 52 weeks, with an…

This study is for adults aged 18 to 65 with moderate to severe ulcerative colitis who are starting etrasimod as part of their regular care. Researchers will track symptom changes over 52 weeks using health questionnaires completed online. The goal is to see if etrasimod helps red…

This study tests whether the medicine abrocitinib can safely improve moderate-to-severe eczema in children aged 6 to 12. About 150 children will be randomly assigned to receive either the study drug or a placebo for 16 weeks. The goal is to see if the medicine clears the skin and…

This study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer that has spread. About 1,410 participants will be randomly ass…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 adults with stage 3 or 4 lung cancer will t…

This study looks at the long-term safety and effects of the drug ritlecitinib for teenagers with severe alopecia areata, a condition causing major hair loss. Participants must have completed a prior Pfizer study on this drug. All will take ritlecitinib daily for up to 3 years, wi…

This study watches how safe and effective Xeljanz is for children aged 2 to 17 with active juvenile arthritis or psoriatic arthritis in everyday Korean clinics. About 10 kids will be followed for up to 44 weeks. The goal is to check for side effects and see how well the medicine …

This study tests a medicine called marstacimab, given as a weekly shot under the skin, to prevent bleeding in children aged 1 to 17 with severe hemophilia A or B. Participants receive the drug for 12 months, and their bleeding rates are compared to their own history from the year…

This study follows 850 people with alopecia areata who are taking the approved drug ritlecitinib. Researchers will measure hair regrowth and quality of life over time in real-world clinics. The goal is to see how well the treatment works outside of controlled trials.

This study is testing a combination of two medicines, aztreonam and avibactam (ATM-AVI), to treat serious bacterial infections in newborns and infants up to 9 months old. The goal is to see how safe the drug is and how the body processes it. The study has two parts: first, a sing…

This study tests a daily pill called ritlecitinib for people with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 adults who haven't been helped by antibiotics will receive either the drug or a placebo for 16 weeks. Research…

This early-stage study tests two drugs—elranatamab (a shot under the skin) and iberdomide (a pill)—in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see how well the combination works. About 87 adults with myelom…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults will rece…

This study tests two experimental medicines (PF-07275315 and PF-07264660) for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams. About 340 participants will receive the drugs or a placebo as injections over several months. The goal is…

This study is observing 600 adults in Korea with ALK-positive metastatic non-small cell lung cancer who are taking the drug Lorviqua as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in everyday medical practice. The goa…

This study tests an experimental drug called PF-07275315 in adults aged 35 to 80 with moderate-to-severe COPD who have had at least two flare-ups in the past year. Participants receive either the drug or a placebo as multiple shots over 24 or 52 weeks. The goal is to see if the d…

This study is checking how safe and effective the drug Cibinqo (abrocitinib) is for people with moderate to severe atopic dermatitis, a type of eczema. About 1,100 participants in Korea will take the tablet by mouth and be followed for one year. Researchers will track side effect…

This study tests a daily pill called ritlecitinib for children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 225 kids will receive either a high dose, low dose, or placebo for 6 months. The goal is to see if the medicine can safely reg…

This early-stage study tests a new drug, PF-08052667, for adults with a type of bladder cancer that hasn't spread into the bladder muscle but is likely to return. The drug is given alone or with standard treatments like BCG and/or sasanlimab. The goal is to check safety and find …

This program offers early access to ritlecitinib, an experimental pill, for people with severe alopecia areata who have lost at least half of their scalp hair and have not improved with standard treatments. The goal is to provide a potential treatment option before the drug is fu…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is given as multiple injections under the skin. The main goal…

This study is testing a new oral medication called osivelotor for people with sickle cell disease. The main goals are to see if the drug can safely increase hemoglobin levels and reduce the frequency of painful vaso-occlusive crises (VOCs). The trial will involve nearly 400 adult…

This study tests whether taking rimegepant around the time of your period can prevent menstrual migraines. About 723 women with regular cycles and a history of menstrual migraines will receive either the drug or a placebo. The goal is to see if rimegepant reduces the number of mi…

This study tests a medicine called rimegepant, a tablet that dissolves under the tongue, to prevent migraines in adolescents aged 12 to 17 who have chronic migraine (15+ headache days per month). About 200 participants will take either rimegepant or a placebo every other day for …

This study tests if the drug rimegepant can prevent migraines in children and teens aged 6 to 18 who have frequent migraines. About 640 participants will receive either the drug or a placebo for 12 weeks. The goal is to see if rimegepant reduces the number of migraine days each m…

This study is testing the long-term safety of a drug called rimegepant for treating migraines in children and adolescents aged 6 to 18. About 600 participants with a history of migraines will take the drug as needed for up to a year. The main goal is to see if the drug is safe an…

This study tests whether the drug rimegepant can safely and effectively stop moderate or severe migraine headaches in children and adolescents aged 6 to 18. About 2100 participants will receive either rimegepant or a placebo. The goal is to see if the drug helps them become pain-…

This study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…

This early-stage study tests a new drug called PF-07832837 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs that it might im…

This study looks at possible eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with the drug TIVDAK. About 100 participants will receive TIVDAK every three weeks and undergo regular eye exams before, during, and after treat…

This study tests the safety of a single dose of zavegepant nasal spray in 16 children aged 6 to 12 who have had migraines for at least 6 months. The medicine is given as one spray into one nostril, and the dose depends on the child's weight. Researchers will monitor how the body …

This study tests a daily oral medication called ritlecitinib for adults with chronic spontaneous urticaria (CSU) — a condition causing itchy hives and deep skin swelling without a clear trigger. About 200 participants who haven't found relief from antihistamines will be randomly …

This study tests whether a new tablet form of tafamidis works the same as the current capsule in healthy adults. About 24 participants will take each version once under fed conditions. The goal is to measure drug levels in the blood, not to treat any disease.

This early-stage study tests a new medicine called PF-07985631, which may one day treat a kidney disease called IgA nephropathy. About 76 healthy adults aged 18 to 55 will receive either the drug or a placebo as a small injection. The main goal is to check safety and how the body…

This study looks at how the body processes different doses of the experimental drug atirmociclib when taken with food. It involves 72 healthy adults aged 18 to 65. The goal is to measure drug levels in the blood and check for side effects, not to treat any disease.

This study looks at how the experimental drug PF-07328948 is absorbed and removed from the body. It involves 8 healthy men aged 18-64 who will take the drug by mouth and by injection. The goal is to learn about the drug's behavior, not to treat any disease.

This study looks at how a new medicine called PF-07328948 moves through the body and how safe it is in people with normal or reduced kidney function. About 28 adults aged 18 to 80 will take a single dose by mouth and stay at a research unit for 6 days. The results will help docto…

This study looks at how the drug vepdegestrant is processed by the body in people with moderate to severe liver problems compared to healthy people. About 24 adults (ages 18-70) will take a single dose and stay at the clinic for 11 days. The goal is to understand how liver functi…

This study tracks the safety of Somatrogon, a growth hormone medicine, in 50 children aged 3 and older with pediatric growth hormone deficiency (short stature). Participants are already prescribed the drug by their doctor and will be followed for up to 3 years for side effects. N…

This early-stage study tests a new tablet form of the experimental COVID-19 drug ibuzatrelvir in 18 healthy adults. Researchers want to see how well the body absorbs the new tablet compared to the original version, and whether taking it with food or as a drink changes absorption.…

This study follows pregnant women with migraine who either took the medication rimegepant or did not, to see how it affects mothers and their babies. Researchers will track birth defects, pregnancy complications, and infant health up to 12 months after birth. The goal is to gathe…

This study looks at how an experimental medicine, PF-08653944, is processed by the body in adults with normal liver function and those with mild to severe liver impairment. Participants receive a single injection and are monitored with blood tests and check-ups. The study does no…

This early-stage study in 16 healthy adults aims to compare how a new tablet form of the experimental drug PF-07799933 is absorbed versus the current version. It also checks if a high-fat meal or an acid-reducing drug changes absorption. No treatment benefit is expected; the goal…

This study observes how safe and effective Zavicefta is for patients with complicated infections in the abdomen, urinary tract, or lungs (pneumonia) that may be linked to hospital stays. About 600 adults and children aged 3 months and older will be followed after receiving the dr…

This study tests two different injector pens that deliver the same medicine (Genotropin) under the skin. Researchers want to see if both pens work the same way in healthy adults aged 18 to 60. Participants will receive one dose with each pen and have blood samples taken to measur…

This study watches pregnant women with eczema who take the medicine CIBINQO (abrocitinib) and compares them to pregnant women with eczema who do not take it. The goal is to see if the medicine affects the baby's health at birth or during the first year of life. About 400 women wi…

This study looks at how much of the medication etrasimod ends up in breast milk. About 8 healthy breastfeeding women will take a daily 2 mg dose for 7 days while staying at a clinic. They cannot breastfeed during the study, so they need an alternative feeding plan. The results wi…

This early-stage study tests a new medicine, PF-07985631, in healthy adults to see if it is safe and how the body handles it. The medicine is being developed for a kidney disease called IgA nephropathy. Participants receive either the drug or a placebo as an injection or IV, and …

This study looks at how the liver processes a new medicine called PF-07328948. Researchers want to see if people with different levels of liver function handle the drug differently. About 26 adults, some with liver problems and some healthy, will take a single tablet and stay at …

This early-stage study tests a medicine called PF-08653944 in 20 adults who are overweight or have obesity. The goal is to see how it changes the speed at which the stomach empties food after a meal. Researchers will also check for side effects. The results will help plan future …

This study looks at how patients with metastatic breast cancer in Sweden are actually using the drug palbociclib in everyday medical practice. Researchers will track 1,500 adults who have filled a prescription for palbociclib to see how long they stay on treatment and how well th…